【摘要】：一、目的：探討英夫利西單抗治療克羅恩病的療效和安全性。方法:2011年l月-2013年10月24例在仁濟(jì)醫(yī)院接受英夫利西單抗治療的24例克羅恩患者，應(yīng)用5mg/kg靜脈滴注第0、2、6周,以后每8周1次,維持30周,觀察第6周及30周的療效。結(jié)果：使用英夫利西單抗治療6周后,患者的臨床癥狀以及血液指標(biāo)明顯改善，治療30周較6周臨床癥狀進(jìn)一步改善，，均無(wú)不良反應(yīng)。結(jié)論：英夫利西單抗對(duì)克羅恩病的治療效果明顯且安全性可，應(yīng)用30周較6周的療效有進(jìn)一步的改善。 二、目的：英夫利西單抗單用及其聯(lián)用硫唑嘌呤的療效和安全性比較。方法：2011年l月-2013年10月仁濟(jì)醫(yī)院?jiǎn)斡糜⒎蚶鲉慰辜捌渎?lián)用硫唑嘌呤治療的各12例克羅恩病患者，英夫利西單抗單用(劑量：5mg/kg靜脈滴注第0、2、6周，后每8周一次維持30周)，第二組在英夫利西單抗第6周加用硫唑嘌呤（劑量：1~2mg/kg/d)。結(jié)果：兩組30周在臨床癥狀和血液指標(biāo)的上無(wú)顯著差異。結(jié)論：英夫利西單抗單用及其聯(lián)用硫唑嘌呤的療效和安全性比較需要進(jìn)一步的臨床隨訪。 三、目的：英夫利西單抗應(yīng)用升階梯和降階梯治療的療效比較。方法：2011年l月-2013年10月仁濟(jì)醫(yī)院12例在疾病早期應(yīng)用英夫利西單抗和9例傳統(tǒng)治療失敗后應(yīng)用英夫利西單抗的克羅恩病患者（劑量：5mg/kg靜脈滴注第0、2、6周，以后每8周1次，維持30周）。結(jié)果：升階梯和降階梯兩組的療效比較沒(méi)有明顯的差異。結(jié)論：升降階梯的治療效果比較需進(jìn)一步臨床隨訪。
[Abstract]:Objective: to investigate the efficacy and safety of infliximab in the treatment of Crohn's disease. Methods: from January 2011 to October 2013, 24 patients with Crohn were treated with Infritemab in Renzi Hospital. The patients were treated with 5mg/kg intravenous drip for 6 weeks, followed by every 8 weeks for 30 weeks. The curative effect was observed at the 6th week and the 30th week. Results: after 6 weeks of treatment, the clinical symptoms and blood indexes of the patients were significantly improved, and the clinical symptoms were further improved at 30 weeks and 6 weeks after treatment, and no adverse reactions were found. Conclusion: the efficacy of infleximab in the treatment of Crohn's disease is obvious and safe, and the effect of 30 weeks treatment is better than that of 6 weeks. Objective: to compare the efficacy and safety of infliximab and its combination with azathioprine. Methods: from January 2011 to October 2013, 12 patients with Crohn's disease were treated with infliximab alone and 12 patients with Crohn's disease treated with azathioprine in Renzi Hospital from January 2011 to October 2013. The second group was treated with azathioprine (1 mg / kg / d) at the 6th week of Inflesi McAb. Results: there was no significant difference in clinical symptoms and blood indexes between the two groups at 30 weeks. Conclusion: the efficacy and safety of infliximab and its combination with azathioprine need further clinical follow-up. Objective: to compare the efficacy of infleximab in the treatment of ascending ladder and descending ladder. Methods: from January 2011 to October 2013, 12 patients with Crohn's disease were treated with infliximab at the early stage of the disease and 9 patients with Crohn's disease after the failure of traditional treatment. For 30 weeks). Results: there was no significant difference between the two groups. Conclusion: further clinical follow-up is needed to compare the therapeutic effect of elevating ladder.
【學(xué)位授予單位】：上海交通大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R574.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 陸星華;;克羅恩病的診治進(jìn)展[J];現(xiàn)代消化及介入診療;2010年04期

2 方衛(wèi)綱,陸星華;腫瘤壞死因子與克羅恩病[J];中華消化雜志;2002年04期

3 Renato Caviglia;Mentore Ribolsi;Marina Rizzi;Sara Emerenziani;Maria Laura Annunziata;Michele Cicala;;Maintenance of remission with infliximab in inflammatory bowel disease: Effi cacy and safety long-term follow-up[J];World Journal of Gastroenterology;2007年39期

4 Patricia L Kozuch;Stephen B Hanauer;;Treatment of inflammatory bowel disease:A review of medical therapy[J];World Journal of Gastroenterology;2008年03期

5 丁紀(jì)明;左和寧;楊偉峰;;英夫利西單抗與硫唑嘌呤對(duì)難治性克羅恩病患者的療效分析[J];臨床醫(yī)學(xué)工程;2013年08期

本文編號(hào)：2237347